Developing targeted cancer treatments requires an in depth understanding of cancer biology, its genetic vulnerabilities, and its symbiotic interactions within the tumor microenvironment. Our team of renowned cancer biologists and expert drug developers is applying its knowledge base across these fields to develop new therapeutic candidates that address cancer with the full picture in mind.
View the latest news and press releases from Sporos BioDiscovery
View all newsApr 12, 2024
American Association for Cancer Research (AACR) 2024: TEAD1/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity
View PresentationMar 6, 2024
Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2024
HOUSTON, Texas., March 6, 2024 — Sporos BioDiscovery, Inc. (a portfolio company of Sporos Bioventures,…
READ MOREApr 17, 2023
Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023
SPR1-0117 is a novel isoform-selective inhibitor of TEAD1 / TEAD4 Preclinical data show inhibition of…
READ MORE